Visceral Pain - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Visceral Pain - Pipeline Review, H2 2018’, provides an overview of the Visceral Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Visceral Pain

- The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects

- The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Visceral Pain

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Anavex Life Sciences Corp

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Astellas Pharma Inc

Cadila Healthcare Ltd

Chromocell Corp

Echo Pharmaceuticals BV

Eisai ...

Addex Therapeutics Ltd

Anavex Life Sciences Corp

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Astellas Pharma Inc

Cadila Healthcare Ltd

Chromocell Corp

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Grunenthal GmbH

Idera Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Pfizer Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Visceral Pain – Overview

Visceral Pain – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Visceral Pain – Overview

Visceral Pain – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Visceral Pain – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Visceral Pain – Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Anavex Life Sciences Corp

Arena Pharmaceuticals Inc

Artelo Biosciences Inc

Astellas Pharma Inc

Cadila Healthcare Ltd

Chromocell Corp

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Grunenthal GmbH

Idera Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Pfizer Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Visceral Pain – Drug Profiles

ADX-71743 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-1066 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit NLRP3 for Interstitial Cystitis and Uveitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ART-26.12 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-8464 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl sulfoxide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-2508 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-16357 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRT-6010 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-665 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICE-3682 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide DR2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-08 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesalamine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-6860 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-03 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-188 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXN-677 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olorinab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block Nav1.9 Channel for Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPA1 for Acute Pani and Chronic Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize OXTR for Abdominal Pain and Chronic Visceral Pain – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZH-853 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYKR-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Visceral Pain – Dormant Projects

Visceral Pain – Discontinued Products

Visceral Pain – Product Development Milestones

Featured News & Press Releases

May 22, 2018: Alivio Therapeutics Announces Issuance of Two U.S. Patents Broadly Covering Compositions of Matter for Inflammation-Targeting Technology Platform

Jul 13, 2017: PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology

Nov 14, 2016: Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain

Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Nov 19, 2012: First patient dosed with Namisol in a Phase II trial in patients with chronic post-surgical abdominal pain

Oct 15, 2012: First patient dosed with Namisol in a second phase II study in Chronic Pancreatitis

Oct 06, 2011: First Chronic Pancreatitis patient dosed with Namisol

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Visceral Pain, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Visceral Pain, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Visceral Pain – Pipeline by Addex Therapeutics Ltd, H2 2018

Visceral Pain – Pipeline by Anavex Life Sciences Corp, H2 2018

Visceral Pain – Pipeline by Arena Pharmaceuticals Inc, H2 2018

Visceral Pain – Pipeline by Artelo Biosciences Inc, H2 2018

Visceral Pain – Pipeline by Astellas Pharma Inc, H2 2018

Visceral Pain – Pipeline by Cadila Healthcare Ltd, H2 2018

Visceral Pain – Pipeline by Chromocell Corp, H2 2018

Visceral Pain – Pipeline by Echo Pharmaceuticals BV, H2 2018

Visceral Pain – Pipeline by Eisai Co Ltd, H2 2018

Visceral Pain – Pipeline by Eli Lilly and Co, H2 2018

Visceral Pain – Pipeline by Grunenthal GmbH, H2 2018

Visceral Pain – Pipeline by Idera Pharmaceuticals Inc, H2 2018

Visceral Pain – Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Visceral Pain – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Visceral Pain – Pipeline by Kytogenics Pharmaceuticals Inc, H2 2018

Visceral Pain – Pipeline by Lipella Pharmaceuticals Inc, H2 2018

Visceral Pain – Pipeline by Pfizer Inc, H2 2018

Visceral Pain – Pipeline by UCB SA, H2 2018

Visceral Pain – Pipeline by Urigen Pharmaceuticals Inc, H2 2018

Visceral Pain – Pipeline by Xigen SA, H2 2018

Visceral Pain – Dormant Projects, H2 2018

Visceral Pain – Dormant Projects, H2 2018 (Contd..1), H2 2018

Visceral Pain – Dormant Projects, H2 2018 (Contd..2), H2 2018

Visceral Pain – Dormant Projects, H2 2018 (Contd..3), H2 2018

Visceral Pain – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Visceral Pain, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Visceral Pain, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports